Keywords: آپیکسابان; Atrial fibrillation; New oral anticoagulants; Apixaban; Drug monitoring;
مقالات ISI آپیکسابان (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: آپیکسابان; Dabigatran; Rivaroxaban; Apixaban; Atrial fibrillation; Cancer; Anticoagulants;
Keywords: آپیکسابان; Direct oral anticoagulants; apixaban; nonvalvular atrial fibrillation; appropriate dose; recurrence of ischemic stroke; inappropriate low dose;
Keywords: آپیکسابان; Atrial fibrillation; Bleeding risk; Dronedarone; Apixaban; Warfarin;
Keywords: آپیکسابان; Type 2 diabetes; Direct oral anticoagulants levels; Dabigatran; Rivaroxaban; Apixaban; Hemoclot® Thrombin Inhibitor Assay; Atrial fibrillation;
Keywords: آپیکسابان; Apixaban; Aspirin; Bleeding; Dabigatran; Direct-acting oral anticoagulant; Gastrointestinal; Hospitalization; Intervention; Mortality; Rivaroxaban; Severity; Transfusion; Warfarin;
Keywords: آپیکسابان; Stroke; dabigatran; rivaroxaban; apixaban; edoxaban; oral anticoagulants;
Keywords: آپیکسابان; Photolysis; Solar light irradiation; Surface water; Apixaban; Dabigatran; Rivaroxaban;
Keywords: آپیکسابان; Deep Vein Thrombosis; Anticoagulant drugs; Thrombolytic therapy; Mechanical thrombolysis; Rivaroxaban; Apixaban; Edoxaban; Dabigatran; Warfarin;
Keywords: آپیکسابان; Antiplatelet drugs; apixaban; bleeding; dabigatran; direct oral anticoagulants; disseminated intravascular coagulation; edoxaban; liver disease; rivaroxaban; vascular abnormalities; vitamin K deficiency; warfarin;
Keywords: آپیکسابان; Antiphospholipid syndrome; Direct oral anticoagulants; Rivaroxaban; Apixaban; Dabigatran; Thrombosis;
Keywords: آپیکسابان; Novel oral anticoagulants; Dabigatran; Rivaroxaban; Apixaban; New oral anticoagulants use assessment;
Keywords: آپیکسابان; Apixaban; Anticoagulation; Catheter ablation; Atrial fibrillation; Bleeding complication;
Keywords: آپیکسابان; Apixaban; Dabigatran; DOACs; Edoxaban; Measurement; Reversal; Rivaroxaban;
Keywords: آپیکسابان; Absorption; Anticoagulation; Apixaban; Bariatric surgery; Biliopancreatic diversion; Bleeding; Dabigatran; Edoxaban; Efficacy; Gastrectomy; Gastric banding; Obesity; Pharmacokinetics; Rivaroxaban; Roux-en-Y; Safety; Thrombosis; Warfarin;
Keywords: آپیکسابان; Atrial fibrillation; Cost-utility; Cost-effectiveness; Apixaban; Acenocoumarol; Novel anticoagulants;
Keywords: آپیکسابان; Direct oral anticoagulant; Dabigatran; Rivaroxaban; Apixaban; Edoxaban; Randomized clinical trials;
Validated spectrofluorimetric methods for the determination of apixaban and tirofiban hydrochloride in pharmaceutical formulations
Keywords: آپیکسابان; Spectrofluorimetry; Apixaban; Tirofiban HCl; Method validation; Pharmaceutical formulations;
Keywords: آپیکسابان; apixaban; cost-effectiveness; direct oral anticoagulant; venous thromboembolism;
Keywords: آپیکسابان; Atrial fibrillation; Vitamin K antagonists; Dabigatran; Rivaroxaban; Apixaban;
Keywords: آپیکسابان; Acute coronary syndrome; Anticoagulation; Apixaban; Dual antiplatelet therapy; Triple antithrombotic therapy; Warfarin;
Keywords: آپیکسابان; apixaban; dabigatran; postoperative bleeding; rivaroxaban; tooth extraction
Keywords: آپیکسابان; Apixaban; Dabigatran; Direct thrombin inhibitors; Edoxaban; Factor Xa inhibitors; Rivaroxaban;
Keywords: آپیکسابان; Idarucizumab; Andexanet alfa; DOAC; NOAC; Dabigatran; Rivaroxaban; Apixaban; Edoxaban; Antidote; Praxbind; ANNEXA-A; ANNEXA-R;
Keywords: آپیکسابان; Dabigatran; Rivaroxaban; Apixaban; Warfarin; Praxbind; Factor Xa inhibitors; Andexanet alfa;
Keywords: آپیکسابان; Apixaban; Bleeding management; Clinical trials; Dabigatran; Direct oral anticoagulants; Edoxaban; Rivaroxaban;
Keywords: آپیکسابان; Tromboembolia venosa; Apixabán; Artroplastia; Reemplazo de cadera; Reemplazo de rodilla; Análisis de rentabilidad económica; Venous thromboembolism; Apixaban; Hip replacement arthroplasty; Knee replacement arthroplasty; Cost-benefit analysis;
Keywords: آپیکسابان; Anticoagulant; Apixaban; Degradation; Spectrophotometry; Stability-indicating
Keywords: آپیکسابان; Anticoagulación oral; Fibrilación auricular; Dabigatran; Rivaroxaban; Apixaban; Edoxaban;
Keywords: آپیکسابان; Anticoagulation; Novel oral anticoagulants; Rivaroxaban; Apixaban; Edoxaban; Dabigatran
Keywords: آپیکسابان; Intracranial hemorrhage; Cerebral bleeding; Anticoagulants; Warfarin; Rivaroxaban; Apixaban; Dabigatran
Keywords: آپیکسابان; Thrombophrophylaxis; Rivaroxaban; Apixaban; Total hip arthroplasty; Total knee arthroplasty; NOAC; Venous thromboembolism (VTE);
Keywords: آپیکسابان; adherence; anticoagulant; apixaban; atrial fibrillation; rivaroxaban;
Keywords: آپیکسابان; apixaban; bioavailability; crushed tablet; food effect; formulation; stability;
Keywords: آپیکسابان; LC-MS/MS; Direct oral anticoagulants; Coagulation tests; Chromogenic assay; Rivaroxaban; Edoxaban; Apixaban; Dabigatran;
Keywords: آپیکسابان; Apixaban; Dabigatran; Intracranial hemorrhages; Rivaroxaban; Treatment outcome
Keywords: آپیکسابان; warfarin; anticoagulation; dabigatran; rivaroxaban; apixaban;
Keywords: آپیکسابان; anticoagulation; apixaban; cutaneous surgery; dabigatran; novel drugs; rivaroxaban; warfarinCYP3A4, cytochrome P450 3A4; NOAC, novel oral anticoagulant; P-gp, permeability glycoprotein
Keywords: آپیکسابان; Tromboembolismo venoso; Dabigatrán; Rivaroxabán; Apixabán; EdoxabánVenous thromboembolism; Dabigatran; Rivaroxaban; Apixaban; Edoxaban
Keywords: آپیکسابان; Bleeding; New oral anticoagulants; Rivaroxaban; Dabigatran; Apixaban; Meta-analysis;
Keywords: آپیکسابان; apixaban; bioavailability; crushed tablet; nasogastric tube;
Keywords: آپیکسابان; Elderly; Nonvalvular atrial fibrillation; Guidelines; Vitamin K antagonists; Dabigatran; Rivaroxaban; Apixaban; EdoxabanAnciano; Fibrilación auricular no valvular; Guías; Antagonistas de la vitamina K; Dabigatran; Rivaroxaban; Apixaban; Edoxaban
Keywords: آپیکسابان; Anciano; Fibrilación auricular no valvular; Guías; Antagonistas de la vitamina K; Dabigatran; Rivaroxaban; Apixaban; EdoxabanElderly; Nonvalvular atrial fibrillation; Guidelines; Vitamin K antagonists; Dabigatran; Rivaroxaban; Apixaban; Edoxaban
Keywords: آپیکسابان; anticoagulant; antiplatelet; apixaban; blood thinners; dabigatran; dermatologic surgery; dietary supplements; prasugrel; rivaroxaban; ticagrelorADP, adenosine diphosphate; AF, atrial fibrillation; CVA, cerebrovascular accident; FDA, Food and Drug Administ
Keywords: آپیکسابان; Novel oral anticoagulants; Apixaban; Dabigatran; Edoxaban; Rivaroxaban; Cost-effectiveness; Atrial fibrillationNovos anticoagulantes orais; Apixabano; Dabigatrano; Edoxabano; Rivaroxabano; Custo-efetividade; Fibrilhação auricular
Keywords: آپیکسابان; apixaban; cost-effectiveness; nonvalvular atrial fibrillation; Japan;
Keywords: آپیکسابان; anticoagulation; apixaban; atrial fibrillation; cost-effectiveness; dabigatran; rivaroxaban;
Keywords: آپیکسابان; AF; SPAF; Dabigatran; Rivaroxaban; Apixaban;
Keywords: آپیکسابان; apixaban; atrial fibrillation; clinical impact; cost-effectiveness; edoxaban;
Keywords: آپیکسابان; Aspirin; Apixaban; Dabigatran; Edoxaban; Rivaroxaban; Oral anticoagulants; Pulmonary embolism; Venous thromboembolism; Venous thrombosis